JP2021183631A - CD8+CD45RClow Tregの新しい亜集団およびその使用 - Google Patents
CD8+CD45RClow Tregの新しい亜集団およびその使用 Download PDFInfo
- Publication number
- JP2021183631A JP2021183631A JP2021133065A JP2021133065A JP2021183631A JP 2021183631 A JP2021183631 A JP 2021183631A JP 2021133065 A JP2021133065 A JP 2021133065A JP 2021133065 A JP2021133065 A JP 2021133065A JP 2021183631 A JP2021183631 A JP 2021183631A
- Authority
- JP
- Japan
- Prior art keywords
- human
- cells
- treg
- ifnγ
- cd45rc low
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003289 regulatory T cell Anatomy 0.000 title claims abstract description 335
- 102000003814 Interleukin-10 Human genes 0.000 claims abstract description 245
- 108090000174 Interleukin-10 Proteins 0.000 claims abstract description 242
- 102100033499 Interleukin-34 Human genes 0.000 claims abstract description 237
- 101710181549 Interleukin-34 Proteins 0.000 claims abstract description 236
- 210000004027 cell Anatomy 0.000 claims abstract description 206
- 238000000034 method Methods 0.000 claims abstract description 109
- 230000003248 secreting effect Effects 0.000 claims abstract description 73
- 239000012472 biological sample Substances 0.000 claims abstract description 35
- 208000024908 graft versus host disease Diseases 0.000 claims abstract description 27
- 238000000338 in vitro Methods 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 230000002829 reductive effect Effects 0.000 claims abstract description 8
- 230000001105 regulatory effect Effects 0.000 claims abstract description 8
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 526
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 99
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 80
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 75
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 70
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 30
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 30
- 210000004698 lymphocyte Anatomy 0.000 claims description 28
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 21
- 102000005962 receptors Human genes 0.000 claims description 10
- 108020003175 receptors Proteins 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract description 22
- 239000000427 antigen Substances 0.000 description 101
- 108091007433 antigens Proteins 0.000 description 95
- 102000036639 antigens Human genes 0.000 description 95
- 230000000735 allogeneic effect Effects 0.000 description 52
- 239000002609 medium Substances 0.000 description 52
- 108090000623 proteins and genes Proteins 0.000 description 50
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 47
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 47
- 102000004169 proteins and genes Human genes 0.000 description 47
- 235000018102 proteins Nutrition 0.000 description 46
- 230000002401 inhibitory effect Effects 0.000 description 44
- 108010002350 Interleukin-2 Proteins 0.000 description 40
- 102000000588 Interleukin-2 Human genes 0.000 description 40
- 230000028993 immune response Effects 0.000 description 39
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 36
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 36
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 36
- 102000004127 Cytokines Human genes 0.000 description 35
- 108090000695 Cytokines Proteins 0.000 description 35
- 230000003321 amplification Effects 0.000 description 35
- 238000003199 nucleic acid amplification method Methods 0.000 description 35
- 108090000765 processed proteins & peptides Proteins 0.000 description 33
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 26
- 150000001413 amino acids Chemical group 0.000 description 26
- 102000003812 Interleukin-15 Human genes 0.000 description 25
- 108090000172 Interleukin-15 Proteins 0.000 description 25
- 230000014509 gene expression Effects 0.000 description 24
- 230000001225 therapeutic effect Effects 0.000 description 24
- 239000012636 effector Substances 0.000 description 23
- 206010020751 Hypersensitivity Diseases 0.000 description 22
- 208000023275 Autoimmune disease Diseases 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 230000028327 secretion Effects 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- -1 Foxp3 Proteins 0.000 description 18
- 206010052779 Transplant rejections Diseases 0.000 description 18
- 230000012010 growth Effects 0.000 description 18
- 230000007815 allergy Effects 0.000 description 17
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 16
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 16
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 15
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 15
- 241000700605 Viruses Species 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 238000001514 detection method Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 238000002955 isolation Methods 0.000 description 13
- 239000003550 marker Substances 0.000 description 13
- 238000000684 flow cytometry Methods 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 11
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 11
- 208000037976 chronic inflammation Diseases 0.000 description 11
- 238000012258 culturing Methods 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 10
- 210000000612 antigen-presenting cell Anatomy 0.000 description 10
- 210000003162 effector t lymphocyte Anatomy 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 108091008874 T cell receptors Proteins 0.000 description 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 9
- 239000013566 allergen Substances 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 102000047758 human TNFRSF18 Human genes 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 9
- 239000003018 immunosuppressive agent Substances 0.000 description 9
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 8
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 8
- 102000006386 Myelin Proteins Human genes 0.000 description 8
- 108010083674 Myelin Proteins Proteins 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000001506 immunosuppresive effect Effects 0.000 description 8
- 210000005012 myelin Anatomy 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 7
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 102000056003 human IL15 Human genes 0.000 description 7
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000010257 thawing Methods 0.000 description 7
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 6
- 108010036949 Cyclosporine Proteins 0.000 description 6
- 230000005867 T cell response Effects 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 229940125721 immunosuppressive agent Drugs 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000004068 intracellular signaling Effects 0.000 description 6
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 6
- 229960004866 mycophenolate mofetil Drugs 0.000 description 6
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- 229930105110 Cyclosporin A Natural products 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 101000998132 Homo sapiens Interleukin-34 Proteins 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
- 229960004784 allergens Drugs 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 5
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 5
- 229960004584 methylprednisolone Drugs 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 229960002930 sirolimus Drugs 0.000 description 5
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000007492 two-way ANOVA Methods 0.000 description 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 4
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 4
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000004544 dc2 Anatomy 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 102000052620 human IL10 Human genes 0.000 description 4
- 102000002580 human interleukin-34 Human genes 0.000 description 4
- 230000006058 immune tolerance Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229960001967 tacrolimus Drugs 0.000 description 4
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 102000009093 Dihydrolipoyllysine-residue acetyltransferase Human genes 0.000 description 3
- 108010073112 Dihydrolipoyllysine-residue acetyltransferase Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010054218 Factor VIII Proteins 0.000 description 3
- 102000001690 Factor VIII Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 108010002586 Interleukin-7 Proteins 0.000 description 3
- 102000000704 Interleukin-7 Human genes 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 3
- 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 3
- 206010034277 Pemphigoid Diseases 0.000 description 3
- 108010010974 Proteolipids Proteins 0.000 description 3
- 102000016202 Proteolipids Human genes 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 208000000594 bullous pemphigoid Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229960000301 factor viii Drugs 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 102000055277 human IL2 Human genes 0.000 description 3
- 238000011577 humanized mouse model Methods 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 210000004248 oligodendroglia Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000021 stimulant Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108010022794 2',3'-Cyclic-Nucleotide Phosphodiesterases Proteins 0.000 description 2
- 102100040458 2',3'-cyclic-nucleotide 3'-phosphodiesterase Human genes 0.000 description 2
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 2
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- 101710145634 Antigen 1 Proteins 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000003915 DNA Topoisomerases Human genes 0.000 description 2
- 108090000323 DNA Topoisomerases Proteins 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 101710129990 Eukaryotic initiation factor 4A-III Proteins 0.000 description 2
- 102100022461 Eukaryotic initiation factor 4A-III Human genes 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 2
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 2
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 2
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100022341 Integrin alpha-E Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000008192 Lactoglobulins Human genes 0.000 description 2
- 108010060630 Lactoglobulins Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 102100035917 Peripheral myelin protein 22 Human genes 0.000 description 2
- 101710199257 Peripheral myelin protein 22 Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 235000014443 Pyrus communis Nutrition 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 102100028601 Transaldolase Human genes 0.000 description 2
- 108020004530 Transaldolase Proteins 0.000 description 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 101710187882 Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- 102000013127 Vimentin Human genes 0.000 description 2
- 102000004248 Zinc Transporter 8 Human genes 0.000 description 2
- 108090000702 Zinc Transporter 8 Proteins 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 210000003068 cdc Anatomy 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 201000010276 collecting duct carcinoma Diseases 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000002641 enzyme replacement therapy Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 102000054350 human CHI3L1 Human genes 0.000 description 2
- 235000006486 human diet Nutrition 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 206010022498 insulinoma Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 108010028309 kalinin Proteins 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- NHSMWDVLDUDINY-UHFFFAOYSA-N 2-(2-cyanoethoxy)ethyl prop-2-enoate Chemical compound C=CC(=O)OCCOCCC#N NHSMWDVLDUDINY-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101710150350 Albumin-2 Proteins 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 241000256837 Apidae Species 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 241000713826 Avian leukosis virus Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 102100021334 Bcl-2-related protein A1 Human genes 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000714266 Bovine leukemia virus Species 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 0 CC(C([C@@](C)(*=C1)I)P)C1(S)I Chemical compound CC(C([C@@](C)(*=C1)I)P)C1(S)I 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 108010084976 Cholesterol Side-Chain Cleavage Enzyme Proteins 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 102100040836 Claudin-1 Human genes 0.000 description 1
- 108090000600 Claudin-1 Proteins 0.000 description 1
- 102000018159 Claudin-11 Human genes 0.000 description 1
- 108050007280 Claudin-11 Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000012432 Collagen Type V Human genes 0.000 description 1
- 108010022514 Collagen Type V Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010026206 Conalbumin Proteins 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101150034979 DRB3 gene Proteins 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 102100031920 Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial Human genes 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102100035650 Extracellular calcium-sensing receptor Human genes 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 108010061711 Gliadin Proteins 0.000 description 1
- 102000050627 Glucocorticoid-Induced TNFR-Related Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 1
- 102100028966 HLA class I histocompatibility antigen, alpha chain F Human genes 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010024164 HLA-G Antigens Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 108010085241 Heterogeneous-Nuclear Ribonucleoprotein D Proteins 0.000 description 1
- 102000031528 Heterogeneous-Nuclear Ribonucleoprotein D Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000894929 Homo sapiens Bcl-2-related protein A1 Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 1
- 101000986080 Homo sapiens HLA class I histocompatibility antigen, alpha chain F Proteins 0.000 description 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 1
- 101000591210 Homo sapiens Receptor-type tyrosine-protein phosphatase-like N Proteins 0.000 description 1
- 101000899806 Homo sapiens Retinal guanylyl cyclase 1 Proteins 0.000 description 1
- 101000664703 Homo sapiens Transcription factor SOX-10 Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108010036012 Iodide peroxidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 102100027064 Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial Human genes 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 229940122255 Microtubule inhibitor Drugs 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001197446 Mus cypriacus Species 0.000 description 1
- 101100260032 Mus musculus Tbx21 gene Proteins 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 101150051337 NRP1 gene Proteins 0.000 description 1
- 101000744152 Naja oxiana Cytotoxin 2 Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 101100150900 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) svf-1 gene Proteins 0.000 description 1
- 108010077641 Nogo Proteins Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 101100278514 Oryza sativa subsp. japonica DRB2 gene Proteins 0.000 description 1
- 108010064983 Ovomucin Proteins 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010060932 Postoperative adhesion Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241001506137 Rapa Species 0.000 description 1
- 102100034091 Receptor-type tyrosine-protein phosphatase-like N Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 102100029831 Reticulon-4 Human genes 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 206010058141 Skin graft rejection Diseases 0.000 description 1
- 102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 description 1
- 108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 108010015330 Steroid 17-alpha-Hydroxylase Proteins 0.000 description 1
- 102000001854 Steroid 17-alpha-Hydroxylase Human genes 0.000 description 1
- 108010011732 Steroid 21-Hydroxylase Proteins 0.000 description 1
- 102000014169 Steroid 21-Hydroxylase Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000010265 Sweet syndrome Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102100027188 Thyroid peroxidase Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100038808 Transcription factor SOX-10 Human genes 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 description 1
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 description 1
- 102100031638 Tuberin Human genes 0.000 description 1
- 108050009309 Tuberin Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 229940127174 UCHT1 Drugs 0.000 description 1
- 102100040373 UDP-glucuronosyltransferase 2B17 Human genes 0.000 description 1
- 101710200687 UDP-glucuronosyltransferase 2B17 Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 244000195452 Wasabia japonica Species 0.000 description 1
- 235000000760 Wasabia japonica Nutrition 0.000 description 1
- SAZUGELZHZOXHB-UHFFFAOYSA-N acecarbromal Chemical compound CCC(Br)(CC)C(=O)NC(=O)NC(C)=O SAZUGELZHZOXHB-UHFFFAOYSA-N 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000013633 acquired hemophilia Diseases 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000011198 co-culture assay Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical class 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000010013 cytotoxic mechanism Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 108010003123 dihydrolipoamide acyltransferase Proteins 0.000 description 1
- 108010079167 dihydrolipoamide succinyltransferase Proteins 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 102000005525 fibrillarin Human genes 0.000 description 1
- 108020002231 fibrillarin Proteins 0.000 description 1
- 108060002895 fibrillin Proteins 0.000 description 1
- 102000013370 fibrillin Human genes 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 108010025934 hnRNP A2 Proteins 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 108040006870 interleukin-10 receptor activity proteins Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 238000011527 multiparameter analysis Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 108010064578 myelin proteolipid protein (139-151) Proteins 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100001223 noncarcinogenic Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 108010013351 sodium-iodide symporter Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- SZCZSKMCTGEJKI-UHFFFAOYSA-N tuberin Natural products COC1=CC=C(C=CNC=O)C=C1 SZCZSKMCTGEJKI-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 108010046241 vestitone reductase Proteins 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Abstract
Description
本発明は、ヒトCD8+CD45RClowTregの高度に抑制的な亜集団の同定を含む細胞療法の分野に関する。
免疫抑制レジメンは依然として、移植片の長期生存および移植患者の安寧にとって大きな障害であり、主に二次的影響および非特異的免疫抑制により、ここ数年は同種移植片の生存率の改善が停滞している(Feng 2008)。ドナー抗原への優れた抑制能力および特異性を有する調節集団のヒトにおける同定は、ヒトの移植、および制御性T細胞(Treg)/エフェクターT細胞(Teff)調節不全を伴う多数の疾患において大きな関心が寄せられている。
第一の態様において、本発明は、IFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowT制御性(Treg)細胞の単離集団に関する。
本発明は、高度に抑制性のCD8+Treg亜集団の同定から得られる。詳細には本発明者らは、CD8+CD45RClowTregのIFNγ+IL−10+IL−34+分泌亜集団の高度に抑制性の亜集団を同定した。本発明者らは、抗ドナーCD4+CD25−エフェクターT細胞応答に対する古典的CD4+CD25highCD127lowTregに比較したそれらの優れた能力と、それらの抑制活性におけるIFNγ、IL−10およびIL−34の役割を実証した。加えて本発明者らは、IFNγ+IL−10+IL−34+分泌CD8+CD45RClowTregの特異的増幅、ならびにヒト化マウスを用いてヒト皮膚移植片拒絶およびGVHDを阻害する移植での細胞療法としてのそれらの能力を記載した。
第一の態様において、本発明は、CD8+Tregの単離集団、詳細にはIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowT制御性(Treg)細胞の単離集団に関する。本発明はまた、GITR+および/またはFoxp3+であるIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowT制御性(Treg)細胞の単離集団に関する。
本発明のCD8+ヒトTregの亜集団、詳細には本明細書の先に記載されたCD8+CD45RClowTreg細胞の亜集団は、細胞表面マーカーと、IFNγ、IL−10およびIL−34を生成するそれらの能力とによって操作的に特徴づけられ得る。
REEYARFDSDVGEYR(SEQ ID NO:1);
NREEYARFDSDVGEYR(SEQ ID NO:2);
REEYARFDSDVGEFR(SEQ ID NO:3);
REEYVRFDSDVGEYR(SEQ ID NO:4);
QEEYARFD SD VGEYR(SEQ ID NO:5);
REEYARFDSDVGVYR(SEQ ID NO:6);
NREEYARFDSDVGEFR(SEQ ID NO:7);
NREEYVRFDSDVGEYR(SEQ ID NO:8);
NQEEYARFDSDVGEYR(SEQ ID NO:9);
NREEYARFDSDVGVYR(SEQ ID NO:10);
RLLARLIYNREEYARFDSDVGEYRAVTELGRPSAEYRNKQ(SEQ ID NO:11);
YLRYDSDVGEYRAVTE(SEQ ID NO:12);
DSDVGEYRAVTELGRP(SEQ ID NO:13);
YLRYDSDVGEYR(SEQ ID NO:14);
YLRYDSDVGEYRAV(SEQ ID NO:15);
SDVGEYRAVTELGR(SEQ ID NO:16);
LRYDSDVGEYRAVTE(SEQ ID NO:17)、
からなる群から選択される。
本発明はまた、本明細書の先に記載されたIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞の細胞集団を濃縮する方法であって
− 本明細書の先に記載された通りヒト末梢血単核細胞(PBMC)またはリンパ球を含有する生体試料中のIFNγ+IL−10+IL−34+を分泌する該CD8+CD45RClowTreg細胞を検出すること、
− 前記細胞を選択し、
それによりIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞が濃縮された細胞集団を得ること、
を含む、方法に関する。
− ヒト末梢血単核細胞(PBMC)またはリンパ球を含有する生体試料を、ヒトCD8+CD45RClowTreg細胞の集団を単離するのに有用な手段と接触させること、
− 該CD8+CD45RClowTreg細胞から該IFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞を検出および選択し、
それによりIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞の濃縮された細胞集団を得ること、
を含む。
− ヒト末梢血単核細胞(PBMC)またはリンパ球を含有する生体試料を、非CD8+細胞のマーカーに結合する少なくとも1種の試薬と接触させ、それにより非CD8+細胞を除去すること、
− 本明細書の先に記載されたIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞を検出し、それらを選択し、
それによりIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞の濃縮された細胞集団を得ること、
を含み得る。
− ヒト末梢血単核細胞(PBMC)またはリンパ球を含有する生体試料を、非CD8+細胞のマーカーに結合する少なくとも1種の試薬と接触させ、それにより非CD8+細胞を除去すること、
− 本明細書の先に記載されたCD8+CD45RClowTreg細胞を検出および単離すること、および
− 該CD8+CD45RClowTreg細胞から本明細書の先に記載されたIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞を検出および選択し、
それによりIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞の濃縮された細胞集団を得ること、
を含む。
− 本明細書の先に記載されたヒト末梢血単核細胞(PBMC)またはリンパ球を含有する生体試料において、IFNγ+IL−10+IL−34+を分泌する該CD8+CD45RClowTreg細胞を検出すること、
− 前記細胞を除去すること、
−それによりIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞が除去された細胞集団を得ること、
を含む、IFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞の細胞集団を除去する方法に関する。
第三の態様において、本発明は、IFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞の単離集団を培養するステップ、好ましくはIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞の単離集団を、Treg細胞を増幅させるのに適した培地と接触させるステップを含む、本明細書の先に記載されたIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞を増幅させる方法に関する。
− ヒト末梢血単核細胞(PBMC)またはリンパ球を含有する生体試料からCD8+GITR+Treg細胞を単離すること、場合によりヒト末梢血単核細胞(PBMC)またはリンパ球を含有する生体試料からCD8+CD45RClowGITR+Treg細胞を単離すること、
− 場合により該単離されたTreg細胞を凍結し、続いて解凍すること、および
− 前記細胞を培養で増幅させること、
を含む、本発明によるCD8+Treg細胞の集団を生成する方法に関する。
− ヒト末梢血単核細胞(PBMC)またはリンパ球を含有する生体試料から、IFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞であるCD8+GITR+Treg細胞を単離すること、
− 場合により該単離されたTreg細胞を凍結し、続いて解凍すること、および
− 前記細胞を培養で増幅させること、
を含む。
− ヒト末梢血単核細胞(PBMC)またはリンパ球を含有する生体試料からCD8+GITR+Treg細胞を単離すること、場合によりヒト末梢血単核細胞(PBMC)またはリンパ球を含有する生体試料からCD8+CD45RClowGITR+Treg細胞を単離すること、
− 場合により該単離されたTreg細胞を凍結し、続いて解凍すること、および
− 前記細胞を培養で増幅させること、
を含む、IFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞の集団を生成する方法に関する。
− ヒト末梢血単核細胞(PBMC)またはリンパ球を含有する生体試料から、CD8+GITR+Treg細胞を単離すること、
場合により該単離されたTreg細胞を凍結し、続いて解凍すること、および
− 前記細胞を培養で増幅させること、
を含む。
− ヒト末梢血単核細胞(PBMC)またはリンパ球を含有する生体試料から、CD8+CD45RClowGITR+Treg細胞を単離すること、
− 場合により該単離されたTreg細胞を凍結し、続いて解凍すること、および
− 前記細胞を培養で増幅させること、
を含む。
− ヒト末梢血単核細胞(PBMC)またはリンパ球を含有する生体試料において、CD8+GITR+Treg細胞を検出すること、場合によりヒト末梢血単核細胞(PBMC)またはリンパ球を含有する生体試料において、CD8+CD45RClowGITR+Treg細胞を検出すること、
− 前記細胞を除去すること、
− それによりIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞が除去された細胞集団を得ること、
を含む、本発明のCD8+Tregの集団を除去する方法に関する。
本発明はまた、本発明のCD8+ヒトTregの、詳細には本発明によるIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞の集団、好ましくは本発明のCD8+ヒトTregの、詳細にはIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞の単離集団を含む組成物を提供する。一実施形態において、本発明による組成物は、本発明のCD8+ヒトTregの、詳細にはIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞の濃縮集団を含む。一実施形態において、本発明による組成物は、本発明のCD8+ヒトTregが除去された細胞集団、詳細にはIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞が除去された集団を含む。別の実施形態において、本発明による組成物は、本発明の遺伝子改変CD8+ヒトTregの集団、詳細には遺伝子改変IFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞の集団を含む。
上述の通り、本発明のCD8+ヒトTregの、詳細には本発明のIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞の単離集団は、免疫系による自己組織または治療性タンパク質の変性を回避するための自己免疫性、慢性炎症、アレルギー、移植(移植片拒絶またはGVHDを予防または処置するため、のいずれか)、遺伝子療法および治療性タンパク質での処置の分野で関心が寄せられている。本発明によるヒトCD8+CD45RClowTreg細胞の単離集団は、事実、免疫寛容を誘導する能力、ならびに/または免疫反応、好ましくは処置される疾患に関与する抗原(複数可)に対する抗原特異性免疫反応(複数可)および/もしくはCD4+T細胞、CD8+T細胞により介在される望まない獲得免疫反応、好ましくは免疫T細胞寛容またはT細胞活性化の低減を抑制および/もしくは阻害する能力を示す。好ましくは本発明のCD8+ヒトTregの、詳細には本発明のIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞の単離集団は、処置される患者から単離される(そしてエクスビボ増幅後に患者に再投与される)。
別の態様において、本発明は、患者が移植片拒絶、GVHD、慢性炎症性疾患、自己免疫疾患、治療性タンパク質への望まない免疫反応またはアレルギー(上記定義)のリスクがあるか否かを決定するためのインビトロ法であって、本発明の方法により前記患者から得られた生体試料中の本発明のCD8+ヒトTregの、詳細には本明細書の先に記載されたIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞の存在を決定するステップを含み、本発明のCD8+ヒトTregの存在、詳細には本明細書の先に記載されたIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞の存在が、移植片拒絶、GVHD、慢性炎症性疾患、自己免疫疾患、治療性タンパク質への望まない免疫反応またはアレルギーのリスク低減の指標である、インビトロ法に関する。
材料と方法
健常な志願者の血液採取およびPBMC分離:
血液を、Etablissement Francais du Sang(フランス、ナント所在)で、健常なドナーから採取した。この試験の認可を、当該協会の審査委員会から得た。記入されたインフォームドコンセントが、当該協会のガイドラインに従って提供された。血液をPBSで二倍希釈した後、PBMCを2000rpm、室温で20のブレーキを用いないFicoll−Paque密度勾配遠心分離(Eurobio、フランスのコートアボフ所在)により単離した。採取されたPBMCを1800rpmで10分間、PBS 50mLで洗浄して、残留する赤血球および血小板を、低浸透性溶液中、5分間のインキュベーションおよび1000rpmで10分間の遠心分離の後に排除した。指示されれば、PBMCをDMSO:SVF 1:9中に凍結し、解凍の間、培地−10%SVFで2回洗浄した。
B細胞(CD19+細胞)および残りの単球(CD14+およびCD16+細胞)のエルトリエーション(DTC Plateforme、ナント所在)および磁気除去(Dynabeads、Invitrogen)による陰性選択と、その後のレスポンダー細胞としてのCD3+CD4+CD25−細胞、CD8+TregとしてのCD3+CD4−CD45RClow、およびCD4+Treg細胞としてのCD3+CD4+CD25−CD127low細胞の選別により、T細胞をPBMCから得た。解凍されたPBMCから選別されたTregを、250U/ml IL−2の存在下、抗CD3および抗CD28 mAbで24時間刺激した後、播種した。IFNγおよび/またはIL−10分泌細胞を、Miltenyiの分泌アッセイ検出キットを用いたTregの24時間ポリクローナル刺激の後、選別した。FACS ARIA I(BD Biosciences、カリフォルニア州マウンテンビュー所在)を用いて、細胞を選別した。
インターロイキン、IFNγおよびFoxp3の分析のために、PBMCを、PMA(50ng/ml)およびイオノマイシン(1μg/ml)で7時間、最後の4時間はBrefeldine A(10μg/ml)の存在下で刺激した。
Treg抑制活性を、同種APCで刺激された同系エフェクターCD4+CD25−T細胞(Tregのドナーから得られた)で評価した。刺激物質:エフェクター比の範囲を、DCで刺激された時にレスポンダー細胞の顕著な増殖に到達するようにテストして、他の実験はAPC:レスポンダー比 1:1で実行した。ブロッキングmAbまたはアイソタイプ対照mAbを、共培養の0日目に50μg/mlで添加した。トランスウェル膜(0.4μMφ)を用いて、両者とも刺激細胞と接触させながら、Tregをレスポンダー細胞から隔離した。1000U/ml IL−2(Miltenyi)を添加して、Tregによるサイトカイン損失を評定した。解凍されたPBMCから増幅されたTregの抑制活性を、増幅に用いられたものと同じドナーから得られた同種APCで刺激された同系エフェクター細胞で評定し、解凍されたPBMCと同じドナーから選別された非刺激Tregに比較した。5%AB血清培地での共培養の4.5日後に、CD3+CD4+生存細胞(DAPI陰性)でゲーティングして、添加の際にCPD−V450標識CD4+Tregを除去することにより、CFSE標識レスポンダー細胞の増殖をフローサイトメトリーで分析した。
Tregを、IL−2(1000U/ml)およびIL−15(10ng/ml)を補充された5%AB血清培地に約3×105個/mlで播種して、1:4のTreg:APC比のコーティング抗CD3 mAb(1μg/ml)、可溶性抗CD28 mAb(1μg/ml)および/または同種APCで刺激した。7日目に、増幅された細胞を1×105個/mlに希釈して、再度刺激した、または刺激しなかった。IL−2およびIL−15サイトカインを、0、7、10および12日目に新たに添加した。14日目に、増幅されたTregを使用前にPBSで洗浄した。
8〜12週齢NOD/SCID/IL−2Rγ−/−(NSG)マウスを、SPF条件の本発明者らの動物施設にて飼育した。この試験は、Pays de la Loire(承認番号CEEA.2012.155)のCommittee on the Ethics of Animal Experimentsにより認可されたプロトコルを厳密に遵守して実施した。
ヒトCD8+CD45RClowTregはヒトCD4+CD25+CD127−Tregよりも効率的な抗ドナー免疫反応抑制物質である
過去の試験で、MHCミスマッチ心臓同種移植片ラットモデルにおけるCD40Igでの処置により誘導された移植片受容におけるCD8+CD45RClowT制御性細胞の関与が記載されている(Guillonneau et al.,2007;Li et al.,2010)。両方の試験で、CD40Ig誘導性同種移植片受容におけるIFNγの重要な役割が強調された。
ヒトCD8+CD45RClowTregを特徴づけるために、詳細な表現型分析を、13色フローサイトメトリーを利用して実施した。複数のマーカー、即ち、CD103、CTLA−4、GITRなどのTreg、またはIFNγ、IL−34もしくはIL−10などのサイトカインについて過去に記載されたマーカーに加え、ヒトCD8+Tregの公知マーカー、即ちCD28およびCD122を分析して、全CD8+CD45RClowTregサブセット内の亜集団の存在を評定した。
IFNγおよびIL−34を発現するヒトCD8+CD45RClowTregの亜集団の抑制能力を評定した。最初に、CD8+CD45RClowTregの亜集団を、IFNγ−またはIL−10−分泌アッセイ検出キットを用いて、IFNγおよびIL−10の発現に基づいて選別して、生存細胞の選別を可能にした。IL−34の大部分がIL−10分泌細胞により共発現されるという観察から、IL−10+細胞がIL−34+細胞でもあると仮定した。したがってCD8+CD45RClowTregの4つの亜集団:IL−10−(IL−34−)IFNγ−、IL−10−(IL−34−)IFNγ+、IL−10+(IL−34+)IFNγ−、およびIL−10+(IL−34+)IFNγ+CD8+CD45RClowTregを選別した。そのような選別された細胞をその後、先に記載された通りMLRアッセイで添加した(図5A)。重要なこととして、IL−10+(IL−34+)IFNγ+CD8+CD45RClowTregは、IL−10−(IL−34−)IFNγ+CD8+CD45RClowTregよりも有意に抑制性であり、IL−10およびIL−34の重要な役割が示唆された。
全CD8+CD45RClowTreg集団を細胞表面マーカー:GITR、CD38、HLA−DR、CD45RA、CD127、CD197、CD27、CD28、CD25で細分することにより、類似のアッセイを実施した。抑制活性の小さな損失が、CD45RAおよびCD28などの一部の他のマーカーで観察され得たが、有意差はなかった。1つの例外を含み、抑制活性の上昇はなく、これらのマーカーを用いて抑制活性を有するCD8+CD45RClowTregをさらに識別し得ないことが示唆された。
その後、CD8+CD45RClowTregの抑制活性の基礎となり得る異なる作用機序を再考した。そのような作用機序としては、サイトカイン分泌、接触依存性活性、エフェクターT細胞増殖を抑制するIL−2除去または殺傷が挙げられる。
CD8+CD45RClowTreg介在性抑制にとっての接触の重要性を決定するために、トランスウェル実験を実施した(図7)。下部チャンバーにおける同種T細胞除去PBMCで刺激されたCFSE標識CD4+CD25−T細胞の増殖を、下部または上部チャンバーにおいてCD8+CD45RClowTregの存在下、または非存在下で評定した。CD8+CD45RClowTregを上部チャンバー内で別個に添加した場合に、抑制活性の完全な損失が観察され、接触の必要性が実証された。
CD4+Tregを用いた細胞療法は、同種移植片の拒絶を予防するための有望な対策であり、CD8+CD45RClowTregは、CD4+CD25highCD127−Tregよりも効率的にエクスビボでの抗ドナー免疫反応を阻害するため(図1)、CD8+CD45RClowTregの増幅のプロトコルを設定した。
重要なこととして、同種およびポリクローナル増幅CD8+CD45RClowTregの両方は、解凍された、選別された、および非増幅CD8+CD45RClowTregよりも、同種CD4+CD25−エフェクターT細胞応答の抑制が有意に効率的であった(図11)。
IFNγの検出を、異なるCD8+CD45RClowTreg培養物の上清で評定した(図13)。単離されたCD8+CD45RClowTregを、ポリクローナル抗CD3および抗CD28 Abで一晩刺激し、MLRアッセイに添加して、同系エフェクターCD4+CD25−T細胞を1:1のエフェクター:サプレッサー比の同種T細胞除去PBMCで刺激するか、または0日目に1:4のTreg:APC比の同種T細胞除去PBMCで刺激して14日間の増幅でポリクローナル抗CD3および抗CD28 Abで刺激した。7日目に、細胞を抗CD3および抗CD28 Abで再度刺激した。0、7、10および12日目に、培地にIL−2およびIL−15を補充した。IFNγを、14日目にELISAにより培養上清で測定した。IFNγ分泌は、エフェクターCD4+CD25−T細胞およびAPC(平均2.5ng/ml)の存在下で検出可能であったが、CD8+Treg(平均3.9ng/ml)との6日間インキュベーション後、または抗CD3および抗CD28 mAbでのCD8+ Treg(平均8.7ng/ml)の14日間増幅後に増加した。
最後に、そのような増幅CD8+CD45RClowTregの抑制能力を、NSGマウスを用いた2つの異なる移植モデル、同種PBMCの注射後のヒト皮膚の同種移植片拒絶モデル(図14)およびヒトPBMCの注射後の異種GVHDモデル(図15)を用いて評定した。
本出願全体を通して、様々な参考資料に、本発明がかかわる技術分野の最新技術が記載されている。これらの参考資料の開示は、参照により本開示に組み入れられる。
Feng S.2008 Long−term management of immunosuppression after pediatric liver transplantation:is minimization or withdrawal desirable or possible or both? Curr Opin Organ Transplant.Oct;13(5):506−12.
Guillonneau,C.,Hill,M.,Hubert,F.X.,Chiffoleau,E.,Herve,C.,Li,X.L.,Heslan,M.,Usal,C.,Tesson,L.,Menoret,S.,et al.2007.CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells,IFN−gamma,and indoleamine 2,3−dioxygenase.J Clin Invest 117:1096−1106.
Li,X.L.,Menoret,S.,Bezie,S.,Caron,L.,Chabannes,D.,Hill,M.,Halary,F.,Angin,M.,Heslan,M.,Usal,C.,et al.2010.Mechanism and localization of CD8 regulatory T cells in a heart transplant model of tolerance.J Immunol 185:823−833.
Picarda,E.,Bezie,S.,Venturi,V.,Echasserieau,K.,Merieau,E.,Delhumeau,A.,Renaudin,K.,Brouard,S.,Bernardeau,K.,Anegon,I.,et al.2014.MHC−derived allopeptide activates TCR−biased CD8+ Tregs and suppresses organ rejection.J Clin Invest 124:2497−2512.
Sadelain M,Brentjens R,Riviere I.2013 The basic principles of chimeric antigen receptor(CAR)design;Cancer Discov.April;3(4):388−398.
Streuli,M.,Hall,L.R.,Saga,Y.,Schlossman,S.F.,and Saito,H.1987.Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens.J Exp Med 166:1548−1566.
Claims (5)
- IFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowT制御性(Treg)細胞の単離集団と少なくとも1種の医薬的に許容できる担体とを含む、必要とする患者においてGVHDを予防または処置するための方法における使用のための医薬組成物。
- 前記Treg細胞が、キメラ抗原受容体(CAR)またはキメラ自己抗体受容体(CAAR)を含む遺伝子改変されたTreg細胞である、請求項1に記載の医薬組成物。
- 前記Treg細胞が、GITR+Foxp3+である、請求項1または2に記載の医薬組成物。
- 患者にGVHDのリスクがあるか否かを決定するためのインビトロ法であって、
ヒト末梢血単核細胞(PBMC)またはリンパ球を含有する生体試料からIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞を検出および/または単離するための方法であって、
(a)前記ヒトPBMCまたはリンパ球の集団を、ヒトCD8+CD45RClowTreg細胞の集団を単離するのに有用な手段と接触させる工程と;
(b)ステップ(a)で得られたヒトCD8+CD45RClowTreg細胞の単離集団を、IFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞を単離するのに有用な手段と接触させる工程と;
を含み、
前記ヒトCD8+CD45RClowTreg細胞の集団を単離するのに有用な手段が、モノクローナル抗ヒトCD3抗体、モノクローナル抗ヒトCD8抗体およびモノクローナル抗ヒトCD45RC抗体からなる少なくとも3つの抗体の組み合わせであり、
前記IFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞を単離するのに有用な手段が、IFNγとCD3、CD8、CD45RCから選択されるT細胞に特異的な細胞表面分子とに結合する二重特異性抗体、IL−10とCD3、CD8、CD45RCから選択されるT細胞に特異的な細胞表面分子とに結合する二重特異性抗体およびIL−34とCD3、CD8、CD45RCから選択されるT細胞に特異的な細胞表面分子とに結合する二重特異性抗体からなる群から選択される少なくとも2つの二重特異性抗体の組み合わせである、
方法により、前記患者から得られた生体試料中のIFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞の存在を決定するステップを含み、
IFNγ+IL−10+IL−34+分泌ヒトCD8+CD45RClowTreg細胞の存在がGVHDのリスクの低減を示す、
インビトロ法。 - 前記Treg細胞が、GITR+Foxp3+である、請求項4に記載のインビトロ法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15306366.4 | 2015-09-07 | ||
EP15306366 | 2015-09-07 | ||
JP2018511706A JP2018527932A (ja) | 2015-09-07 | 2016-09-06 | CD8+CD45RClow Tregの新しい亜集団およびその使用 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018511706A Division JP2018527932A (ja) | 2015-09-07 | 2016-09-06 | CD8+CD45RClow Tregの新しい亜集団およびその使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021183631A true JP2021183631A (ja) | 2021-12-02 |
JP7254128B2 JP7254128B2 (ja) | 2023-04-07 |
Family
ID=54196910
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018511706A Pending JP2018527932A (ja) | 2015-09-07 | 2016-09-06 | CD8+CD45RClow Tregの新しい亜集団およびその使用 |
JP2021133065A Active JP7254128B2 (ja) | 2015-09-07 | 2021-08-18 | CD8+CD45RClow Tregの新しい亜集団およびその使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018511706A Pending JP2018527932A (ja) | 2015-09-07 | 2016-09-06 | CD8+CD45RClow Tregの新しい亜集団およびその使用 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20180251731A1 (ja) |
EP (1) | EP3347452B1 (ja) |
JP (2) | JP2018527932A (ja) |
KR (1) | KR20180054663A (ja) |
CN (1) | CN108291203A (ja) |
AU (1) | AU2016318762B2 (ja) |
BR (1) | BR112018004454A2 (ja) |
CA (1) | CA2997646C (ja) |
ES (1) | ES2890818T3 (ja) |
IL (1) | IL257891B (ja) |
MX (1) | MX2018002849A (ja) |
WO (1) | WO2017042170A1 (ja) |
ZA (1) | ZA201801265B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201834669A (zh) | 2017-03-15 | 2018-10-01 | 美商歐卡生物系統公司 | 用於造血幹細胞移植的組合物及方法 |
EP3652306A1 (en) | 2017-07-13 | 2020-05-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/-tregs |
WO2019141774A1 (en) * | 2018-01-19 | 2019-07-25 | Miltenyi Biotec Gmbh | Regulatory t cell expressing a chimeric antigen receptor |
AU2019218792A1 (en) | 2018-02-08 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for allogenic hematopoietic stem cell transplantation |
WO2019178314A1 (en) * | 2018-03-14 | 2019-09-19 | Thermogenesis Corporation | Buoyancy-activated cell sorting (bacs)-compatible activation/transduction systems and methods |
WO2020102503A2 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
WO2020120786A1 (en) | 2018-12-14 | 2020-06-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs |
EP3963053A4 (en) * | 2019-04-30 | 2023-01-18 | The Regents of the University of California | BEADLESS EX-VIVO MULTIPLICATION OF HUMAN REGULATING T LYMPHOCYTES |
WO2024028486A1 (en) * | 2022-08-04 | 2024-02-08 | Nantes Universite | In vitro method for obtaining clinical-grade cd8+ cd45rclow/- regulatory t cells |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5340001A (en) * | 2000-04-11 | 2001-10-23 | Univ Southern California | A method to prevent graft rejection using tgf-beta to induce t suppressor cells |
WO2008095141A2 (en) * | 2007-01-31 | 2008-08-07 | Yeda Research And Development Co. Ltd. | Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
US10137181B2 (en) * | 2014-04-01 | 2018-11-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Isolated donor MHC-derived peptide and uses thereof |
JP6769948B2 (ja) * | 2014-07-17 | 2020-10-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 移植拒絶の予防及び自己免疫疾患の治療に使用するための単離されたインターロイキン−34ポリペプチド |
-
2016
- 2016-09-06 CN CN201680064881.0A patent/CN108291203A/zh active Pending
- 2016-09-06 KR KR1020187009677A patent/KR20180054663A/ko unknown
- 2016-09-06 EP EP16769882.8A patent/EP3347452B1/en active Active
- 2016-09-06 US US15/758,139 patent/US20180251731A1/en not_active Abandoned
- 2016-09-06 WO PCT/EP2016/070991 patent/WO2017042170A1/en active Application Filing
- 2016-09-06 AU AU2016318762A patent/AU2016318762B2/en active Active
- 2016-09-06 ES ES16769882T patent/ES2890818T3/es active Active
- 2016-09-06 CA CA2997646A patent/CA2997646C/en active Active
- 2016-09-06 JP JP2018511706A patent/JP2018527932A/ja active Pending
- 2016-09-06 MX MX2018002849A patent/MX2018002849A/es unknown
- 2016-09-06 BR BR112018004454A patent/BR112018004454A2/pt active Search and Examination
-
2018
- 2018-02-23 ZA ZA2018/01265A patent/ZA201801265B/en unknown
- 2018-03-05 IL IL257891A patent/IL257891B/en active IP Right Grant
-
2021
- 2021-08-18 JP JP2021133065A patent/JP7254128B2/ja active Active
Non-Patent Citations (3)
Title |
---|
CHAN, W. K. ET AL.: "Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen m", LEUKEMIA, vol. 29, no. 2, JPN6022036044, February 2015 (2015-02-01), pages 387 - 395, XP055403336, ISSN: 0004862682, DOI: 10.1038/leu.2014.174 * |
GUILLONNEAU, C. ET AL.: "CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indol", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 117, no. 4, JPN6020020438, April 2007 (2007-04-01), pages 1096 - 1106, XP002774213, ISSN: 0004862683 * |
XYSTRAKIS, E. ET AL.: "Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regu", BLOOD, vol. 104, no. 10, JPN6022036045, 2004, pages 3294 - 3301, XP002435096, ISSN: 0004862681, DOI: 10.1182/blood-2004-03-1214 * |
Also Published As
Publication number | Publication date |
---|---|
JP7254128B2 (ja) | 2023-04-07 |
EP3347452A1 (en) | 2018-07-18 |
RU2766691C2 (ru) | 2022-03-15 |
ZA201801265B (en) | 2022-08-31 |
CN108291203A (zh) | 2018-07-17 |
CA2997646A1 (en) | 2017-03-16 |
IL257891A (en) | 2018-05-31 |
BR112018004454A2 (pt) | 2018-09-25 |
RU2018107363A (ru) | 2019-10-09 |
CA2997646C (en) | 2024-04-23 |
WO2017042170A1 (en) | 2017-03-16 |
IL257891B (en) | 2020-09-30 |
US20180251731A1 (en) | 2018-09-06 |
AU2016318762A1 (en) | 2018-03-22 |
ES2890818T3 (es) | 2022-01-24 |
RU2018107363A3 (ja) | 2020-02-27 |
KR20180054663A (ko) | 2018-05-24 |
EP3347452B1 (en) | 2021-06-23 |
MX2018002849A (es) | 2018-09-05 |
AU2016318762B2 (en) | 2022-03-31 |
JP2018527932A (ja) | 2018-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7254128B2 (ja) | CD8+CD45RClow Tregの新しい亜集団およびその使用 | |
US8053235B2 (en) | Methods of generating antigen-specific CD4+CD25+regulatory T cells, compositions and methods of use | |
Ferri et al. | A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis | |
ES2765884T3 (es) | Métodos de expansión y evaluación de linfocitos B y uso de linfocitos B expandidos para el tratamiento de enfermedades | |
JP6068432B2 (ja) | 治療における調節性t細胞の使用方法 | |
JP2015513403A (ja) | 同種抗原反応性の制御性t細胞を増大させる方法 | |
CN102947702B (zh) | 分离Tr1细胞的新方法 | |
US20170216417A1 (en) | Population of immunoregulatory t cells specific for an irrelevant antigen and uses thereof for preventing or treating immune diseases | |
KR20140137444A (ko) | 인간 림프 기관-유래 억제성 기질 세포의 분리 및 용도 | |
Sanders et al. | Foxp3+ regulatory T cell therapy for tolerance in autoimmunity and solid organ transplantation | |
KR20130093083A (ko) | Il-13 생산 tr1-유사 세포 및 그의 용도 | |
US20070128670A1 (en) | Methods for the identification and preparation of regulator/suppressor t lymphocytes, compositions and use thereof | |
RU2766691C9 (ru) | НОВАЯ СУБПОПУЛЯЦИЯ CD8+CD45RClow КЛЕТОК TREG И ЕЕ ПРИМЕНЕНИЯ | |
US20180139937A1 (en) | Cell culture systems for producing il-33 induced t9 cells and methods of using the cells | |
CA3058284A1 (en) | Methods to produce peptides, polypeptides or cells for modulating immunity | |
US20150064206A1 (en) | Compositions for treating uveitis | |
Milward | Investigation of the cell biology of human regulatory T cells in the context of transplantation | |
Locafaro | In vitro generation and in vivo characterization of IL-10 engineered T cells suitable for adoptive immunotherapy | |
Kleer | T cell regulation in Juvenile Idiopathic Arthritis: Controlling chronic inflammation by pulling the right strings | |
Romano | In vitro characterisation and expansion of human regulatory T cells for their in vivo application in the induction of tolerance in haematopoietic stem cell and solid organ transplantation | |
Ierino | COMPETING INTERESTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210916 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220830 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221128 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20221201 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230222 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230314 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230328 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7254128 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |